Drugs / [68Ga]Ga-ABY-025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06828588 | Apr 2026 → Dec 2027 expected | breast carcinoma by gene expression profile, metastatic malignant neoplasm | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-ABY-025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06828588 ↗ |
| Modality | Diagnostic / imaging agent | “The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors” NCT06828588 ↗ |
| Route | Intravenous | “Patients will be infused with the study drug, \[68Ga\]Ga-ABY-025, followed by PET/CT imaging post infusion.” NCT06828588 ↗ |